摘要
目的评定美多芭与吡贝地尔联合应用治疗中晚期帕金森病的临床疗效。方法 60例帕金森病患者随机分为单用美多芭对照组(31例)和美多芭联合吡贝地尔治疗组(29例),临床疗效采用改良Webster评分和PD统一评分量表(UPDRS)运动评分进行治疗前后评定。结果治疗后2个月及12个月治疗组Webster评分及UPDRS运动评分明显低于对照组,差异有统计学意义(P<0.05),临床总显效率对照组为51.6%,治疗组为82.8%,治疗组总显效率明显高于对照组(P<0.05)。结论单用美多芭和美多芭联合吡贝地尔治疗帕金森病均有效,而且美多芭联合吡贝地尔比单用美多芭治疗帕金森病有效率更高。
Objective To observe the clinical curative effect of Madopa in conjunction with Piribedil（P） in advanced Pakinson’s disease（PD）. Methods Sixty PD patients were randomly divided into Madopa control group （n=28）and Madopa＋P treatment group（n=28）,The clinical effect was assessed with modified Webster and UPDRS charts before and after treatment. Results 2 months and 12 month after treatment , the Webster score and the UPDRS motor score of the treatment group was significantly lower than the control group, the difference was statistically significant （P0.05）, the marked curative effect rate was 51.6% in control group, while the treatment group is 82.8% .The total marked curative effect rate of the treatment group were significantly higher （P0.05）.Conclusion It was effective to treat PD with Madopa alone or Madopa＋P, the effectiveness was higher when treating with Madopa＋P than Madopa alone.
出处
《中国医药指南》
2010年第13期32-33,共2页
Guide of China Medicine
